Further expands board expertise and gender diversity
Improves corporate governance
BOSTON, May 20, 2022 (GLOBE NEWSWIRE) — Radius Health, Inc. (“Radius” or the “Company”) (RDUS) today announced that it has added two new independent members to the Board of Directors (the “Board”) ). Effective today, Jennifer A. Jarrett and Susan Vissers Lisa joined the board as Class I and Class III directors, respectively. In addition, Radius’ Board of Directors also announced several corporate governance changes to further enhance shareholder engagement.
“I am delighted to welcome Jennifer and Susie to the Radius Board of Directors. Their healthcare acumen and extensive operational experience will be invaluable as Radius seeks to advance its business on behalf of patients, stakeholders and employees,” said Owen Hughes, Chairman of the Board. “Their appointments to our Board of Directors, along with the governance enhancements we are announcing today, build on the changes we have made over the past 24 months to further align our interests with those of our shareholders. .”
The appointments of Ms. Jarrett and Ms. Lisa further broaden the board’s gender diversity and relevant industry expertise, including senior-level experience at large public life sciences companies . Of the 10 directors on the extended board, nine are independent. Six of the company’s current directors, including Ms. Jarrett and Ms. Lisa, have joined the board in the past two years, reflecting a deliberate process of renewal within the company’s leadership.
- Jennifer A. Jarrett, 51, is currently Chief Operating Officer and serves on the Board of Directors of Arcus Biosciences, a clinical-stage global biopharmaceutical company focused on the development of differentiated molecules and combination therapies for people with cancer. She currently sits on the board of directors of Syndax Pharmaceuticals, a clinical-stage biopharmaceutical company developing cancer therapies. She also serves on the board of directors of SMART, a non-profit organization whose mission is to help “first generation” American students access and assimilate into private schools in the Bay Area. Previously, she was Vice President of Corporate Development and Capital Markets at Uber and a member of the boards of Arena Pharmaceuticals and Audentes Therapeutics. Earlier in her career, she held senior positions at Medivation, Citigroup Inc. and Credit Suisse Group AG. Ms. Jarrett holds a BA in Economics from Dartmouth College and an MBA from Stanford University Graduate School of Business.
- Susan Vissers Lisa, 53 years old, most recently served as Senior Vice President, Investor Relations at CVS Health Corporation until April 2022. Prior to this role, Ms. Lisa served as Vice President, Investor Relations at Boston Scientific Corporation for more seven years old. Previously, she served as Senior Director, Investor Relations and Corporate Development at Abiomed and held senior management positions at BofA Securities, Inc. Ms. Lisa began her career at JPMorgan Chase and Cowen Inc. Ms. Lisa earned a bachelor’s degree in economics and political science. from Duke University and an MBA from New York University Stern School of Business. She holds the CFA charter.
Corporate governance improvements
In accordance with best practice in corporate governance, the company’s board of directors has proposed to reduce the vote required to amend the charter and articles of association from a supermajority to a majority of the outstanding shares, subject to approval by Radius shareholders at the next annual meeting this year. In addition, the Board has adopted a “proxy access” provision to allow long-term shareholders to appoint directors in the Company’s proxy statement.
Radius is a global biopharmaceutical company focused on unmet medical needs in bone health, neuroscience diseases and oncology. Radius’ lead product, TYMLOS® (abaloparatide) Injection, has been approved by the US Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk of fracture. Radius’ clinical pipeline includes experimental injection of abaloparatide for potential use in treating men with osteoporosis; an investigational abaloparatide transdermal system for potential use in treating postmenopausal women with osteoporosis; the investigational drug, elacestrant (RAD1901), for potential use in the treatment of hormone receptor positive breast cancer, licensed from the Menarini Group; and the investigational drug RAD011, a synthetic cannabidiol oral solution with potential use in multiple neuroendocrine, neurodevelopmental, or neuropsychiatric disease areas, initially targeting Prader-Willi syndrome, Angelman syndrome, and infantile spasms.
Radius, its directors and certain of its senior executives may be considered participants in the solicitation of proxies from shareholders in connection with the matters to be considered at the 2022 annual meeting. The Company intends to file a circular proxy and a BLUE proxy card with the SEC in connection with such solicitation of proxies from shareholders. SHAREHOLDERS ARE STRONGLY ENCOURAGED TO READ THIS PROXY ANNOUNCEMENT AND THE BLUE PROXY CARD WHEN THEY BECOME AVAILABLE AS THEY WILL CONTAIN IMPORTANT INFORMATION. Information regarding the ownership of the directors and officers of the company in stock and other securities of the company is included in their filings with the SEC on Forms 3, 4 and 5, which can be viewed on the company’s website. the society (www.radiuspharm.com) in the “Investors” section or on the SEC’s website at www.sec.gov. Additional information about the directors and officers of Radius and their interests is set forth in Radius’ Annual Report on Form 10-K for the fiscal year ended December 31, 2021, which was filed with the SEC on February 24, 2022. as amended on May 2, 2022; Radius’ Quarterly Report on Form 10-Q for the fiscal year ended March 31, 2022 which was filed with the SEC on May 5, 2022; and in the Company’s other filings with the SEC, which may be viewed on the Company’s website (www.radiuspharm.com) in the “Investors” section or on the SEC’s website at www.sec.gov. More detailed and updated information regarding the identity of potential participants and their direct or indirect interests, by securities holding or otherwise, will be set forth in the proxy statement and other documents to be filed with the SEC in in connection with the 2022 Annual Meeting. Shareholders will be able to obtain any proxy statement, amendment or supplement to the proxy statement and other materials filed by the Company with the SEC free of charge at the SEC’s website at www.sec.gov. Copies will also be available free of charge on the Company’s website at www.radiuspharm.com.
Contact with Investors and Media Relations:
E-mail: [email protected]
Phone: (617) 583-2017